International trade · 04/03/2026Updated: 10/16/2026 · 1 min read
U.S. International Trade Commission Solicits Comments on Biosimilars Complaint
Summary
The U.S. International Trade Commission is seeking public comments on a complaint regarding biosimilars of Pertuzumab, a biologic drug, and the manufacturing methods used to produce them.
Original source language: Federal Register — International Trade CommissionOpen original release →